Management of pulmonary toxicity associated with immune checkpoint inhibitors.
Journal
European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391
Informations de publication
Date de publication:
31 Dec 2019
31 Dec 2019
Historique:
received:
12
02
2019
accepted:
08
06
2019
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
30
5
2020
Statut:
epublish
Résumé
Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, bladder, head and neck cancers. Besides their efficacy, these agents also generate specific immune-related adverse events. Due to the increasing prescription of immune-checkpoint inhibitors, the incidence of immune toxicity will continue to rise. The awareness of immune-related adverse events is key to ensuring both diagnosis and management of the possible serious adverse events. Although severe immune-related adverse events remain rare, they can lead to discontinued treatment or to death if they are not forecasted and managed properly. Even if lung toxicity is not the most frequent adverse event, it remains critical as it can be life-threatening. Herein, the main aspects of pulmonary toxicity are reviewed and guidelines are also proposed in order to manage the possible side-effects.
Identifiants
pubmed: 31694838
pii: 28/154/190012
doi: 10.1183/16000617.0012-2019
pmc: PMC9488507
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: M. Delaunay has nothing to disclose. Conflict of interest: G. Prévot has nothing to disclose. Conflict of interest: S. Collot has nothing to disclose. Conflict of interest: L. Guilleminault has nothing to disclose. Conflict of interest: A. Didier has nothing to disclose. Conflict of interest: J. Mazières reports grants and personal fees from AstraZeneca, BMS and Roche, and personal fees from Novartis, MSD, Pfizer and Pharmamar, outside the submitted work.
Références
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Cancer Immunol Res. 2016 May;4(5):383-9
pubmed: 26928461
Eur Respir J. 1993 Apr;6(4):477-82
pubmed: 8491296
J Immunother Cancer. 2017 Jul 18;5(1):54
pubmed: 28716137
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
J Clin Oncol. 2012 Jun 10;30(17):e156-9
pubmed: 22547608
Clin Cancer Res. 2016 Dec 15;22(24):6051-6060
pubmed: 27535979
J Thorac Oncol. 2016 Dec;11(12):2048-2050
pubmed: 27866633
Ann Oncol. 2017 Mar 1;28(3):583-589
pubmed: 27998967
Nat Med. 2017 May 5;23(5):540-547
pubmed: 28475571
Ann Oncol. 2016 Apr;27(4):559-74
pubmed: 26715621
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Rev Prat. 2014 Sep;64(7):951-6
pubmed: 25362778
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
Oncologist. 2019 May;24(5):640-647
pubmed: 30777894
Cancer Immunol Res. 2018 Jun;6(6):630-635
pubmed: 29622582
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Rev Mal Respir. 2018 Nov;35(9):963-967
pubmed: 30220489
N Engl J Med. 2017 May 18;376(20):1989-91
pubmed: 28514612
Chemotherapy. 2018;63(5):272-277
pubmed: 30572331
Curr Opin Oncol. 2016 Jul;28(4):269-77
pubmed: 27138570
Clin Microbiol Infect. 2018 Mar;24(3):216-218
pubmed: 29269089
Chest. 2017 Aug;152(2):271-281
pubmed: 28499515
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Eur Respir J. 2017 Aug 10;50(2):
pubmed: 28798088
Eur Respir J. 2006 Aug;28(2):422-46
pubmed: 16880372
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Chest. 2004 Dec;126(6):1750-6
pubmed: 15596669
Eur J Cancer. 2017 Apr;75:308-309
pubmed: 28259013
Ann Oncol. 2017 Mar 1;28(3):673-675
pubmed: 27993808
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
J Chin Med Assoc. 2016 May;79(5):248-55
pubmed: 27036494
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Chest. 2013 Mar;143(3):858-861
pubmed: 23460165
JAMA Oncol. 2016 Dec 01;2(12):1607-1616
pubmed: 27540850
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
J Clin Oncol. 2017 Mar;35(7):709-717
pubmed: 27646942
Cancer Immunol Res. 2018 Sep;6(9):1093-1099
pubmed: 29991499
Lung Cancer. 2017 Sep;111:1-5
pubmed: 28838377
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921